# US Dry Age-Related Macular Degeneration AMD Market

> US Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Users (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.3%
- **2024:** $ 1,332.8 Million
- **2025:** $ 1,443.42 Million
- **2035:** $ 3,203.89 Million
- **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US)

**Report ID:** MRFR/LS/12338-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-dry-age-related-macular-degeneration-amd-market-13863

---

## Market Summary

## US Dry Age-Related Macular Degeneration (AMD) Market Overview

The US Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 1.2 (USD Billion) in 2024 to 2.5 (USD Billion) by 2035. The US Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 6.9% during the forecast period (2025 - 2035).

K**ey US Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted**

The US Dry Age-Related Macular Degeneration (AMD) Market is experiencing noteworthy trends shaped by a combination of demographic shifts and healthcare advancements. The aging population in the US is a significant driver, as individuals aged 65 and older are at a higher risk for developing AMD. This demographic change is becoming evident, with millions of Americans affected, prompting an increased focus on awareness and prevention.

The push for early diagnosis and management of AMD is growing as healthcare providers emphasize the importance of regular eye exams and screening, which aligns with national health initiatives aimed at improving eye health among older adults. Improvements in technologies and treatment options are improving the market economy of the US. New and emerging innovative therapies like nutritional supplements and possible outcome-shifting gene therapies are offering better hope in disease management. The mere fact that diverse biotech firms are trying to devise methods to mitigate the advance of dry AMD portrays positive research and development activity.

Also, there is a movement towards the use of digital health technologies, including mobile applications and telehealth, that enable patients to be educated and monitored remotely, making it convenient for them to access care. There is also a developing trend of collaboration among various actors in the healthcare system, such as researchers, organizations, and ophthalmologists towards addressing the problem of dry AMD. Public awareness campaigns and community programs focused on eye health are on the rise, aiming to educate the population about risk factors and prevention strategies.

This comprehensive approach signals notable progress in addressing dry AMD and reflects a commitment within the US to improve patient outcomes and quality of life.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**US Dry Age-Related Macular Degeneration (AMD) Market Drivers**

**Increasing Aging Population**

The aging population in the US is one of the most significant drivers of growth in the US Dry Age-Related Macular Degeneration (AMD) Market industry. According to the US Census Bureau, by 2030, nearly 1 in 5 Americans will be of retirement age, leading to a higher prevalence of age-related health issues, including AMD. As the likelihood of developing AMD increases with age, this demographic shift directly impacts market growth. The National Eye Institute also anticipates a significant rise in AMD cases, projecting that by 2050, over 5 million Americans will be diagnosed with some form of AMD.

This trend emphasizes the necessity for targeted therapeutic options and enhances the revenue potential within the US Dry Age-Related Macular Degeneration (AMD) Market industry as healthcare providers and pharmaceutical companies develop products to address this growing need.

**Advances in Treatment Options**

Technological advancements in the treatment of AMD are driving market growth within the US Dry Age-Related Macular Degeneration (AMD) Market industry. Ongoing research and clinical trials conducted by esteemed institutions, such as the National Institutes of Health (NIH), are exploring novel therapies, including gene therapy and regenerative medicine, which are showing promising results in combatting AMD. The emphasis on innovative treatment leads to increased investment from both the public and private sectors, driving market expansion.

A reported investment of over $500 million in AMD research from various stakeholders, including pharmaceutical companies and non-profits, showcases a strong commitment to finding effective solutions for AMD, which can significantly enhance patient outcomes.

**Growing Public Awareness and Screening Initiatives**

Public awareness campaigns and screening initiatives significantly impact the US Dry Age-Related Macular Degeneration (AMD) Market industry's growth. Organizations such as the American Academy of Ophthalmology are actively promoting programs aimed at educating the public about the risks and symptoms associated with AMD. Enhanced awareness leads to earlier diagnosis and increased demand for treatment solutions. A CDC report highlighted that early detection through screenings can reduce the risk of blindness by over 50%, prompting older adults to seek preventive measures.

As more individuals become conscious of AMD, the demand for diagnostic and therapeutic options in the US Dry Age-Related Macular Degeneration (AMD) Market industry is expected to rise markedly in the coming years.

**US Dry Age-Related Macular Degeneration (AMD) Market Segment Insights**

**Dry Age-Related Macular Degeneration (AMD) Market Stage Insights**

The US Dry Age-Related Macular Degeneration (AMD) Market is witnessing notable dynamics within its Stage segmentation, which includes early, intermediate, and late age-related macular degeneration. Early age-related macular degeneration represents a critical phase where many individuals may display minimal symptoms, yet this stage holds immense significance as it lays the foundation for potential progression to more advanced stages. Awareness and early intervention strategies in this segment are vital to mitigate the risk of vision loss, as individuals in this phase can benefit from lifestyle modifications and monitoring.

As we move to the intermediate stage, patients often begin experiencing noticeable vision changes, making this segment crucial from a treatment standpoint. The intermediate AMD stage is characterized by the accumulation of drusen and retinal pigment changes that can lead to more significant vision impairment. Understanding the patient demographics and effective treatment options during this stage can leverage market growth opportunities, especially as the population ages. The late age-related macular degeneration stage, often marked by severe vision loss and geographic atrophy, presents unique challenges and stresses the need for comprehensive care approaches.

This segment accounts for a significant portion of the AMD burden and impacts patients' quality of life profoundly. The increased prevalence of late AMD correlates with the growing elderly population in the US, driving healthcare demands and indicating the importance of advanced therapeutic interventions to manage symptoms effectively. Overall, the US Dry Age-Related Macular Degeneration (AMD) Market revenue will likely benefit from innovations across these stages, with insights derived from market growth enabling tailored therapies and preventive strategies to enhance patient outcomes.

This segmentation not only highlights the need for enhanced clinical care but also emphasizes the potential economic impact on healthcare systems. The structure of the US Dry Age-Related Macular Degeneration (AMD) Market segmentation supports a focused approach to the development and delivery of specialized solutions catering to each stage's unique requirements, thereby encouraging comprehensive understanding and research within the industry.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights**

The US Dry Age-Related Macular Degeneration (AMD) Market exhibits significant segmentation by age group, which plays a crucial role in shaping the market landscape. As the population ages, the prevalence of AMD increases notably among individuals above 60 years, where the majority of cases are reported. Specifically, the age group above 75 years is particularly vital, reflecting a pronounced susceptibility to vision impairment caused by AMD, making this demographic a key focus for treatment and intervention strategies.

The increasing life expectancy in the US and rising awareness about eye health are driving factors in this market, leading to growing demand for AMD diagnostics and therapies. Additionally, the above 40 years age group is becoming increasingly relevant as early signs of AMD can start manifesting, emphasizing the need for early detection and preventive measures. This age-specific segmentation allows stakeholders to tailor marketing and product development efforts effectively, addressing the unique needs of each group.

Understanding these dynamics is essential for navigating the US Dry Age-Related Macular Degeneration (AMD) Market industry, as it presents both challenges and opportunities in delivering specialized care and advancing AMD management solutions.

**Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights**

The Diagnosis and Treatment segment of the US Dry Age-Related Macular Degeneration (AMD) Market has been experiencing notable advancements, reflecting the rising prevalence of AMD among the aging population in the U.S. Effective diagnosis techniques are critical as they enable timely intervention, with leading tools including optical coherence tomography and fundus photography playing a vital role in early detection. Meanwhile, the treatment landscape encompasses an array of approaches aimed at managing disease progression and alleviating symptoms, with a focus on nutritional supplements, anti-VEGF therapies, and emerging gene therapies gaining traction.

As the population ages, the demand for innovative treatments is expected to rise, driving industry growth. Moreover, the integration of technology in both diagnosis and treatment is reshaping care, offering improved patient outcomes. With a substantial portion of the elderly population at risk, the significance of this segment cannot be overstated, highlighting an urgent need for continuous evolution in strategies to combat AMD effectively in the U.S.

**Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights**

The Route of Administration segment in the US Dry Age-Related Macular Degeneration (AMD) Market plays a pivotal role in the distribution of therapies aimed at managing this prevalent age-related condition. The importance of the Route of Administration stems from its direct impact on the efficacy and patient compliance associated with treatment regimens. Among the various methods, oral administration has gained traction due to its ease of use and patient-friendly nature, making it accessible to a broader demographic. In contrast, injectables are significant for their ability to deliver targeted therapy, often yielding faster results, particularly in cases requiring immediate intervention.

With the increasing prevalence of AMD in the aging US population, understanding the intricacies of these administration routes is crucial for the development of effective treatment options. As per the Centers for Disease Control and Prevention (CDC), more than 2 million Americans aged 50 and older are affected by AMD, highlighting the pressing need for innovative and efficacious routes of therapy that cater to patient preferences and clinical requirements. As the market evolves, the Route of Administration will likely adapt to technological advancements and changing patient needs, leading to growth opportunities in the segment.

**Dry Age-Related Macular Degeneration (AMD) Market End Users Insights**

The End Users segment of the US Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the overall landscape of eye health services. Hospitals and clinics are at the forefront of diagnosis and treatment, offering specialized care that is essential for managing AMD. Diagnostic centers provide critical services that include advanced imaging and testing, enabling early detection of the disease and facilitating timely interventions. Academic and research institutes contribute significantly to the market through innovation and clinical trials, paving the way for new treatment options and technologies.

The increasing prevalence of AMD in the aging US population drives the demand within these areas, as they are pivotal in providing comprehensive care and educational support. Additionally, advancements in research and technology are enhancing the capabilities of healthcare providers, allowing them to offer more effective and personalized treatment solutions. As the market evolves, collaboration among these End Users will likely be essential in addressing the challenges posed by AMD, thereby improving patient outcomes and shaping future strategies within the market.

**US Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights**

The competitive landscape of the US Dry Age-Related Macular Degeneration (AMD) Market is characterized by dynamic growth and innovation driven by extensive research and development initiatives. This market focuses on the treatment and management of Dry AMD, an affliction primarily affecting the elderly population, with implications for vision health and overall quality of life. Various players in the industry are leveraging advanced technologies and conducting clinical trials to explore novel treatment modalities, thereby enhancing patient outcomes and redefining therapeutic options available for this degenerative eye condition.

The competition is intense, with companies striving to capture market share through strategic partnerships, acquisitions, and the introduction of cutting-edge products that meet the evolving needs of healthcare providers and patients alike. Kite Pharma has established a significant presence within the US Dry Age-Related Macular Degeneration (AMD) Market, primarily focusing on leveraging its expertise in cellular therapies for potential treatment interventions. One of the key strengths of Kite Pharma lies in its commitment to research and its innovative approach to developing therapies that target the underlying causes of AMD.

This company possesses a robust pipeline of product candidates that are designed to address advanced stages of the disease. Additionally, Kite Pharma’s vigorous collaboration with academic institutions and research organizations enhances its capabilities in translating scientific discoveries into viable treatment options for patients suffering from Dry AMD. The organization's emphasis on patient-centric approaches and personalized medicine further solidifies its competitive position in this niche segment of the healthcare industry. Genentech holds a prominent position in the US Dry Age-Related Macular Degeneration (AMD) Market by offering a variety of therapeutics that cater to patients dealing with this condition.

The company is known for its strong portfolio of anti-VEGF agents, which have been instrumental in managing neovascular AMD and hold potential applications in the treatment of dry AMD as well. Genentech's significant investments in research and development have fostered a steady flow of innovative product solutions, solidifying its reputation as a leader in this segment. Along with its robust product offerings, Genentech has engaged in strategic mergers and acquisitions to enhance its research capabilities and broaden its market reach within the US.

Its collaborations with healthcare providers and involvement in community outreach programs further strengthen its market presence, allowing Genentech to act as a critical player in advancing the treatment landscape for Dry AMD and ultimately improving patient outcomes through cutting-edge science and medical advances.

**Key Companies in the US Dry Age-Related Macular Degeneration (AMD) Market Include**

**US Dry Age-Related Macular Degeneration (AMD) Market Industry Developments**

Significant developments have occurred recently in the US Dry Age-Related Macular Degeneration (AMD) market. In July 2023, Apellis Pharmaceuticals announced the FDA approval of its innovative treatment, which has the potential to change the management approach for patients suffering from dry AMD. This approval marks a crucial milestone in the market, addressing an unmet need for effective treatment options. On the merger and acquisition front, in September 2023, Regeneron Pharmaceuticals acquired Iveric Bio, which is expected to bolster Regeneron's pipeline in AMD and optimize collaborative efforts to enhance patient outcomes.

Furthermore, Genentech continues to advance its research and development initiatives, focusing on novel therapies that target AMD in light of the growing patient population projected by the CDC, which estimates that by 2030, nearly 3 million Americans will be affected by AMD. The competitive landscape is further evolving, with increased investment from companies such as Novartis and Kite Pharma, reinforcing their commitment to developing groundbreaking therapies for AMD. The surge in market valuation and research funding reflects a promising trajectory for advancements in AMD care in the US.

**Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights**

## Market Drivers

### Aging Population Dynamics

The demographic shift towards an older population in the US is a primary driver of the dry age-related macular degeneration (AMD) market. As individuals age, the prevalence of age-related eye diseases, including dry AMD, increases significantly. By 2030, it is projected that approximately 20% of the US population will be over 65 years old, leading to a higher incidence of AMD. This demographic trend suggests a growing need for effective treatment options and management strategies within the dry age-related-macular-degeneration-amd market. Furthermore, the aging population is likely to increase healthcare expenditures, which may further stimulate investment in research and development of new therapies and diagnostic tools tailored for this demographic. Thus, the aging population serves as a crucial catalyst for market growth.

### Rising Healthcare Expenditure

In the US, healthcare expenditure continues to rise, which significantly impacts the dry age-related-macular-degeneration-amd market. In 2023, healthcare spending reached approximately $4.3 trillion, with a substantial portion allocated to eye care and vision-related treatments. This increase in spending reflects a growing recognition of the importance of addressing age-related conditions, including dry AMD. As more resources are directed towards innovative therapies and preventive measures, the market is likely to experience enhanced growth. Additionally, the willingness of patients and insurers to invest in advanced treatments may lead to a broader adoption of emerging therapies, thereby expanding the market landscape. The rising healthcare expenditure thus plays a pivotal role in shaping the future of the dry age-related-macular-degeneration-amd market.

### Increased Focus on Preventive Care

The shift towards preventive care in the US healthcare system is influencing the dry age-related-macular-degeneration-amd market. Healthcare providers are increasingly emphasizing the importance of early detection and lifestyle modifications to mitigate the risk of developing AMD. This trend is supported by various public health campaigns aimed at educating the population about the risk factors associated with dry AMD, such as smoking and poor diet. As awareness grows, more individuals are likely to seek regular eye examinations and adopt healthier lifestyles, potentially reducing the incidence of AMD. Consequently, this focus on preventive care may lead to a more proactive approach in managing eye health, thereby impacting the dry age-related-macular-degeneration-amd market positively.

### Advancements in Research and Development

Ongoing advancements in research and development are propelling the dry age-related-macular-degeneration-amd market forward. The US has seen a surge in clinical trials and studies focused on understanding the pathophysiology of dry AMD and developing novel therapeutic approaches. For instance, recent studies have explored the potential of gene therapy and stem cell treatments, which could revolutionize the management of this condition. The National Eye Institute has reported a significant increase in funding for AMD research, indicating a strong commitment to addressing this public health issue. As new findings emerge, they may lead to innovative treatment options that could reshape the dry age-related-macular-degeneration-amd market landscape. This focus on R&D is essential for fostering growth and improving patient outcomes.

### Technological Integration in Treatment Options

Advanced technologies are reshaping treatment options in the dry age-related macular degeneration (AMD) market. Innovations such as telemedicine and digital health platforms are enhancing patient access to care and facilitating remote monitoring of AMD progression. Moreover, the development of artificial intelligence (AI) in diagnostic tools is improving the accuracy of early detection, which is crucial for effective management of dry AMD. As these technologies become more prevalent, they may lead to increased patient engagement and adherence to treatment regimens. The potential for technology to streamline care delivery and improve outcomes suggests a promising future for the dry age-related-macular-degeneration-amd market, as it adapts to the evolving landscape of healthcare.

## Future Outlook

The Dry Age-Related Macular Degeneration AMD Market is projected to grow at an 8.3% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness.

**New opportunities:**

- Development of telemedicine platforms for remote patient monitoring. Investment in AI-driven diagnostic tools for early detection. Expansion of personalized treatment plans based on genetic profiling.

By 2035, the market is expected to achieve substantial growth, driven by innovative solutions and increased demand.

## Segment Insights

### By Stages: Intermediate Age-Related Macular Degeneration (Largest) vs. Late Age-Related Macular Degeneration (Fastest-Growing)

The US dry age-related-macular-degeneration-amd market showcases a varied distribution among the stages of the condition. Early Age-Related Macular Degeneration has a significant share but is overshadowed by Intermediate Age-Related Macular Degeneration, which leads the market due to its broader prevalence. Late Age-Related Macular Degeneration, while comprising a smaller portion of the market, represents a rapidly expanding segment, driven by increasing awareness and healthcare advancements. Growth trends indicate that the Intermediate Age-Related Macular Degeneration segment continues to benefit from earlier detection techniques and improved treatment options. As healthcare providers focus on proactive management strategies, the Late Age-Related Macular Degeneration segment is emerging with faster growth due to an aging population and rising incidence rates. Innovations in therapies are further catalyzing this dynamic landscape as patients seek effective solutions.

Early Age-Related Macular Degeneration (Dominant) vs. Late Age-Related Macular Degeneration (Emerging)

Early Age-Related Macular Degeneration is recognized as the dominant segment within the US dry age-related-macular-degeneration-amd market, characterized by early symptom onset and a significant base of diagnosed cases. This stage is often monitored to prevent progression to more severe forms. In contrast, Late Age-Related Macular Degeneration is an emerging segment, marked by advanced vision loss and a growing patient base due to demographic shifts. Patients with this stage face serious challenges, enhancing the urgency for effective treatment solutions. The market is responding to these needs through targeted therapies and supportive technologies aimed at improving the quality of life for those impacted by advanced forms of the condition.

### By Age Group: Above 75 Years (Largest) vs. Above 60 Years (Fastest-Growing)

In the US dry age-related-macular-degeneration-amd market, the age group of individuals above 75 years constitutes the largest segment, commanding significant market share due to the higher prevalence of the condition in this demographic. The segment above 60 years, while smaller in comparison, is experiencing rapid growth, driven by increasing awareness and screening initiatives that target a broader age range, leading to earlier diagnoses. Growth trends for these age segments are influenced by demographic shifts and lifestyle factors. With the aging population in the US, the demand for treatments tailored to the elderly is expected to rise. Additionally, advancements in technology and innovative therapies are likely to attract more patients from the emerging segment of those aged above 60 years, as they seek proactive management of age-related eye conditions.

Above 75 Years (Dominant) vs. Above 60 Years (Emerging)

The segment above 75 years remains dominant in the US dry age-related-macular-degeneration-amd market due to the high incidence rates of AMD in this age group. Patients in this category often represent a significant portion of eye care visits and treatment regimens, making their needs crucial for healthcare providers. In contrast, the emerging segment of individuals above 60 years reflects a growing awareness of AMD and its implications, with increasing numbers seeking preventive measures and early treatment. This proactive approach is driven by enhanced education about eye health, thereby positioning this segment as an increasingly important target for marketing and healthcare strategies aimed at mitigating the progression of AMD.

### By Route of Administration: Injectables (Largest) vs. Oral (Fastest-Growing)

In the US dry age-related-macular-degeneration-amd market, injectables hold the largest market share due to their effectiveness and direct delivery method that provides immediate results. This segment's prominence is driven by a preference for treatments that ensure optimal bioavailability and targeted action, making injectables the leading choice among healthcare providers and patients alike. On the other hand, oral formulations are emerging rapidly, reflecting a growing patient interest in convenient, non-invasive treatment options. This segment's growth is fueled by ongoing research and development to improve oral drug formulations, making them more appealing for long-term treatment. The increasing recognition of compliance benefits associated with oral medications positions this segment as the fastest-growing alternative in the market.

Injectables (Dominant) vs. Oral (Emerging)

Injectables are characterized by their direct administration for quicker therapeutic effects, making them a dominant force in the market. They typically involve advanced formulations that are designed for optimal absorption and immediate action, catering to patient needs who seek effective treatment for age-related macular degeneration. In contrast, oral medications are emerging as a convenient alternative, with advancements aimed at enhancing bioavailability and patient adherence. They offer an easy-to-administer option, appealing to those hesitant about needles. As manufacturers innovate in oral formulation technology, this segment is likely to capture a growing share of the market, balancing efficiency with patient comfort.

### By End Users: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US dry age-related-macular-degeneration-amd market, the distribution of market share among end users reveals that Hospitals & Clinics hold the largest share. This segment benefits from its established infrastructure and patient influx, making it a critical player in treatment delivery. On the other hand, Diagnostic Centers, while smaller in share, are rapidly gaining traction as specialists focus on early detection and preventive care, illustrating a shift toward targeted interventions. The growth trends in this segment are influenced by several factors, including an aging population that demands more frequent screenings and treatments. Furthermore, advancements in diagnostic technologies are driving the need for specialized centers, fostering innovation. Collaborative efforts between Hospitals, Clinics, and Academic Institutions are expected to propel the development and adoption of new treatment paradigms, enhancing patient outcomes and increasing market competitiveness.

Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals & Clinics are recognized as the dominant force within the US dry age-related-macular-degeneration-amd market due to their comprehensive services and established patient networks. They provide a range of treatments and facilitate access to the latest technologies. In contrast, Diagnostic Centers are emerging as key players focusing on specific aspects of AMD management, emphasizing early diagnosis and tailored strategies. This segment is becoming increasingly vital as early detection leads to better management of the disease. Their adaptability and specialization in diagnostic procedures allow them to meet the rising demand for precision medicine. Together, these segments complement each other, with Hospitals & Clinics providing broad resources and Diagnostic Centers offering targeted care.

## Competitive Benchmarking

The dry age-related macular degeneration (AMD) market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Regeneron Pharmaceuticals (US), Novartis (CH), and Apellis Pharmaceuticals (US) are actively engaged in developing advanced therapies and expanding their market presence. Regeneron Pharmaceuticals (US) focuses on leveraging its expertise in biologics to enhance treatment efficacy, while Novartis (CH) emphasizes a diversified portfolio that includes both established and emerging therapies. Apellis Pharmaceuticals (US) is carving a niche with its novel complement inhibition approach, which appears to address unmet needs in the AMD treatment spectrum. Collectively, these strategies contribute to a dynamic environment where innovation and therapeutic advancements are paramount. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for a variety of treatment options, yet the influence of major companies remains significant, as they drive trends and set benchmarks for quality and efficacy in AMD therapies. In October 2025, Regeneron Pharmaceuticals (US) announced a collaboration with a leading biotechnology firm to develop a next-generation gene therapy for AMD. This strategic move is likely to bolster Regeneron's position in the market by expanding its therapeutic offerings and tapping into the growing demand for innovative treatment modalities. The collaboration underscores the importance of partnerships in accelerating research and development efforts in the AMD space. In September 2025, Novartis (CH) launched a new clinical trial for its latest AMD treatment, which incorporates a novel delivery system aimed at improving patient compliance. This initiative reflects Novartis's commitment to addressing patient needs and enhancing treatment accessibility. The trial's outcomes could potentially reshape treatment protocols and establish new standards in AMD management. In August 2025, Apellis Pharmaceuticals (US) secured a strategic partnership with a prominent research institution to explore combination therapies for AMD. This collaboration is indicative of a broader trend towards integrative approaches in treatment, which may enhance therapeutic outcomes and provide a competitive edge in a crowded market. By aligning with research entities, Apellis aims to leverage cutting-edge science to inform its product development pipeline. As of November 2025, the competitive trends in the dry AMD market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development. Strategic alliances are becoming a cornerstone of competitive strategy, enabling companies to pool resources and expertise. Looking ahead, the focus is likely to shift from price-based competition to differentiation through innovation, technology, and reliable supply chains. This evolution suggests that companies that prioritize R&D and strategic collaborations will be better positioned to thrive in an increasingly complex market.

## Recent News & Developments

Significant developments have occurred recently in the US Dry Age-Related Macular Degeneration (AMD) market. In July 2023, Apellis Pharmaceuticals announced the FDA approval of its innovative treatment, which has the potential to change the management approach for patients suffering from dry AMD. This approval marks a crucial milestone in the market, addressing an unmet need for effective treatment options. On the merger and acquisition front, in September 2023, Regeneron Pharmaceuticals acquired Iveric Bio, which is expected to bolster Regeneron's pipeline in AMD and optimize collaborative efforts to enhance patient outcomes.

Furthermore, Genentech continues to advance its research and development initiatives, focusing on novel therapies that target AMD in light of the growing patient population projected by the CDC, which estimates that by 2030, nearly 3 million Americans will be affected by AMD. The competitive landscape is further evolving, with increased investment from companies such as Novartis and Kite Pharma, reinforcing their commitment to developing groundbreaking therapies for AMD. The surge in market valuation and research funding reflects a promising trajectory for advancements in AMD care in the US.

## Report Scope

| MARKET SIZE 2024 | 1332.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1443.42(USD Million) |
| MARKET SIZE 2035 | 3203.89(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US) |
| Segments Covered | Stages, Age Group, Route of Administration, End Users |
| Key Market Opportunities | Advancements in gene therapy and digital health solutions enhance treatment options in the dry age-related-macular-degeneration-amd market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the dry age-related macular degeneration market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the projected market valuation for the US dry age-related macular degeneration market in 2035?**
A: The projected market valuation for the US dry age-related macular degeneration market in 2035 is $3203.89 Million.

**Q: What was the market valuation for the US dry age-related macular degeneration market in 2024?**
A: The market valuation for the US dry age-related macular degeneration market in 2024 was $1332.8 Million.

**Q: What is the expected CAGR for the US dry age-related macular degeneration market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US dry age-related macular degeneration market during the forecast period 2025 - 2035 is 8.3%.

**Q: Which age group shows the highest market valuation for dry age-related macular degeneration?**
A: The age group above 60 years shows the highest market valuation, with figures reaching $600.0 Million to $1400.0 Million.

**Q: What are the key players in the US dry age-related macular degeneration market?**
A: Key players in the US dry age-related macular degeneration market include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Alcon, Horizon Therapeutics, and Apellis Pharmaceuticals.

**Q: What segment had the highest valuation in the route of administration for dry age-related macular degeneration?**
A: In the route of administration segment, injectables had the highest valuation, ranging from $800.0 Million to $2003.89 Million.

**Q: How does the market valuation for late age-related macular degeneration compare to early and intermediate stages?**
A: The market valuation for late age-related macular degeneration was $533.44 Million to $1281.36 Million, which is comparable to early and intermediate stages.

**Q: What is the market valuation range for hospitals and clinics as end users in the dry age-related macular degeneration market?**
A: The market valuation range for hospitals and clinics as end users is between $800.0 Million and $1900.0 Million.

**Q: What is the market valuation for intermediate age-related macular degeneration in 2024?**
A: The market valuation for intermediate age-related macular degeneration in 2024 was between $532.8 Million and $1281.56 Million.

**Q: What is the projected growth trend for the US dry age-related macular degeneration market?**
A: The projected growth trend for the US dry age-related macular degeneration market indicates a steady increase, with a valuation expected to reach $3203.89 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-dry-age-related-macular-degeneration-amd-market-13863*